Drug Profile

Research programme: antibody-drug conjugates - Janssen Biotech/Mersana Therapeutics

Alternative Names: Antibody-drug conjugate - Janssen Biotech/Mersana Therapeutics

Latest Information Update: 28 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Mar 2026 No recent reports of development identified for research development in Cancer in USA (Parenteral)
06 Jan 2026 Mersana Therapeutics has been acquired by Day One Biopharmaceuticals
03 Feb 2022 Mersana Therapeutics and Janssen Biotech entered into a development and marketing agreement to discover novel antibody-drug conjugates for three undisclosed targets

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com